KRYS News and Press, Krystal Biotech Inc. From 03/12/19

Topline-data from Phase 1/2 clinical trial of KB103 (bercolagene telserpavec) for treatment dystrophic epidermolysis bullosa (DEB) to be announced in 1H 2019 Ancoris, a cGMP facility for clinical and commercial production of KB103, is operational following successful completion of...

New facility expected to meet all clinical and commercial development needs of lead program KB103 A second, larger cGMP facility expected to be completed in 2020 to meet all anticipated future pipeline production requirements PITTSBURGH, March 06, 2019 (GLOBE NEWSWIRE) -- Krystal...

PITTSBURGH, March 04, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (Krystal) (NASDAQ: KRYS), a gene therapy company developing “off-the-shelf” treatments for rare dermatological diseases, announced that Julian S. Gangolli has been elected to Krystal’s Board of Dir...

PITTSBURGH, March 01, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman ...

Overview Of Krystal Biotech I first introduced Krystal Biotech ( KRYS ) as a long idea several months ago after they released compelling data in dystrophic epidermolysis bullosa (DEB). After doing a deep dive, I published a more lengthy research piece explaining why I believed this compa...

PITTSBURGH, Feb. 22, 2019 (GLOBE NEWSWIRE) --   Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chai...

In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more ...

Phase I/II Study KRYS data by YCharts In early October, Krystal Biotech ( KRYS ) reported impressive data from its phase I/II gene therapy trial investigating KB103 as a treatment for dystrophic epidermolysis bulossa ((DEB)), a genetic condition characterized by severe chronic blis...

Introduction In my last article, I outlined the broader investment opportunity in Krystal Biotech ( KRYS ), a unique gene therapy company focused on dermatological conditions. In that article, I gave a surface level overview of their STAR-D (Skin TARgeted Delivery) gene therapy platform...

PITTSBURGH, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman a...